Introduction
Subclinical rejection (SCR) means histologically identified acute rejection with stable graft function (1) . Previous studies have demonstrated that SCR found in protocol biopsy is common early after transplantation and do permanent damage to a renal allograft, contributing to chronic allograft nephropathy (CAN) (1) (2) (3) . CAN is a leading cause of graft failure and is strongly correlated with the number of acute rejection episodes during the first year after renal transplantation (4) . So the interests about the early detection and the treatment of SCR is increasing and this raises the possibility that protocol biopsies which are performed when graft function is stable may be clinically useful by allowing the detection of SCR. However, the risk of complications and unclear results of treatment in SCR patients make it difficult to perform protocol biopsy routinely.
The aim of this study was to evaluate clinical significance of protocol biopsy early after renal transplantation by identifying risk factors for SCR and the effect of anti-rejection therapy for SCR in renal transplantation.
Materials and Methods

1) Patients
From January 2007 to June 2010, 337 renal transplantations were performed in Seoul National University Hospital. Among them, the patients who undertook a clinically-indicated biopsy because of acute rejection before 10 days after transplantation (n=23) and the patients under 18 years (n=61) were excluded. Remained patients were divided into two groups depending on whether protocol biopsies were performed or not; protocol biopsy (＋) group (Protocol Bx (＋)) (n=138) and protocol biopsy (-) group (Protocol Bx (-)) (n=115).
2) Immunosuppression
Immunosuppression protocol was a standardized triple therapy including one of calcineurin inhibitors (cyclosporine A, CsA or taclorimus, Tac), an antiproliferative agent (mycophenolatemofetil, MMF) and a prednisolon (PD). CsA was given targeting level of 100∼250 ng/mL for the first 6 months and 40∼80 ng/mL thereafter. Tac was given targeting 6∼10 ng/mL for the first 6 months and 4∼6 ng/mL thereafter. MMF was given 1,000∼1,500 mg/kg per day, and PD was started at 1 mg/kg per day and was rapidly tapered to less than 5 mg per day (5) . Before 2008, anti-IL2R monoclonal antibody (Simulect Ⓡ ; Novartis, Basel, Switzerland) was used in recipients who were performed deceased donor renal transplantation, had number of human leukocyte antigen (HLA) mismatches more than 3, and after 2008 it was used routinely.
3) Protocol biopsy
Ultrasono-guided needle biopsy was performed 10 days after transplantation. Protocol biopsies were performed using 18-gauge needle under ultrasound guidance. Three cores of tissue were obtained at each biopsy. Renal histopathological analysis was performed using the Banff97 classification(6), a semiquantitative scoring system used for the classification and grading of short and long term changes of a renal transplant. SCR was defined as histologically proven acute rejection without any graft dysfunction, as previously described. To assess feasibility of the protocol biopsy early after transplantation, complications (e.g., hemorrhage, peritonitis, graft loss) were evaluated.
4) Treatment of SCR
Anti-rejection therapy including methylprednisolone 0.5 g per day for 3 days was performed in the patients with evidence of acute T cell mediated rejection (TCR). In the patients with borderline change, some of them were treated and the others were not.
5) Statistics
Data was collected through retrospective review of medical records. Univariate analysis was carried out using the Student t test and the chi-square test. Multivariate analysis was carried out using the multiple logistic regression test. All P values were two sided, and a probability of less than 0.05 was considered significant.
Results
1) Demographics
During the study period, a total of 337 patients received kidney transplantation. Among them children under age 18 (n=61) and adult patients who diagnosed acute rejection before 10 days after transplantation (n=23) were excluded from this study. Demographic data are summarized in detail in Table 1 
2) Prevalence of SCR
Protocol biopsies were performed 10 days after transplantation in 138 patients. Seventy three patients (52.9%) showed normal histology and 65 patients (47.1%) had subclinical rejection; acute antibody-mediated rejection in 2 patients (1.4%), borderline change in 46 patients (33.3%), and acute T-cell mediated rejection (TCR) in 17 patients (12.2%) ( Table 2 ).
3) Risk factors of SCR
Sex and age of recipients, donor age, hypertension, diabetes mellitus, ABO mismatch, number of HLA mismatches, pre-transplant PRA, and immunosuppression protocol were enrolled for univariate analysis on risk factors of SCR. Among them, number of HLA-DR mismatches (P=0.127), 'not to use Simulect Ⓡ ' (P=0.01) were identified as risk factors for SCR (Table 3) .
Excluding the interactions of various factors, risk factors previously identified and number of HLA-A, B mismatches, PRA which had been known as risk factors of SCR already were enrolled for multivariate Fig. 1 . Changes in mean MDRD GFR of each group. There were no significant differences between two groups in GFR after 3 months. *P＜0.05. Fig. 2 . δGFR defines as a result of subtraction MDRD GFR at 1 wk from MDRD GFR at the point. There were significant differences between two groups in δGFR at 1, 3, 6, 9, 12, 24 and 36 months. *P＜0.05.
analysis. 'Not to use Simulect ® ' (OR=0.219, 95% CI 0.074∼0.650, P=0.006) was identified as an independent risk factor of SCR (Table 4 ).
4) Short and long-term renal function improvement
To prove the effect of treatment in SCR, patients were newly classified into two groups. Among the patients who undertook protocol biopsy, untreated patients despite of borderline change were divided into the same group with the patients who did not undertake protocol biopsy (Treatment (-) group, n=138). Other patients, who received treatment in the case of SCR as well as undertook protocol biopsy were divided into treated group (Treatment (＋) group, n=43).
GFR at 1 week, 1, 3, 6, 9, 12, 24, and 36 months after transplantation were checked in all patients. GFR change (δGFR) before and after protocol biopsy were calculated by subtracting GFR at 1 week from GFR at that point. There were no significant differences between two groups in GFR (Fig. 1) . However, there were significant differences between two groups in δ GFR at 1, 3, 6, 9, 12, 24 and 36 months with P value less than 0.05 (Fig. 2) . The δGFR curve of treated group shows steady increase whereas δGFR curve of untreated group shows decrease after 12 months.
5) Complication of protocol biopsy
Among 138 patients underwent protocol biopsy, there were only 2 patients (1.4%) major complications in this study. One was bleeding required transfusion and the other was biopsy induced arteriovenous fistula in the renal parenchyme. There was no serious complication such as graft loss or patient death.
Discussion
Protocol biopsy has not been routinely performed because of its invasive character but some recent studies reported that protocol biopsy can provide benefits without major biopsy related complications (7) (8) (9) . In this study, the complication rate was very low and only 2 patients (1.4%) suffered from biopsy-related complication.
According to previous studies, the incidence of SCR was reported to be 38% by Masin-Spasovska et al. (10) and 43% by Rush et al. (11) . In this study, the incidence of SCR was 45.7%. Considering this high prevalence of SCR and its risk contributing to CAN, early detection of SCR with protocol biopsy and appropriate treatment should be required.
It is known that SCR is influenced by the time after transplantation, prior acute rejections, number of HLA mismatches, and immunosuppression (12) . Previously known factors were not identified as independent risk factors of SCR in this study. This may be caused by the retrospective nature of this study. In addition, se-lected patients with deceased donor or HLA mismatches greater than 2 were received Simulect Ⓡ as an induction agent in the early period of this study. According to previous studies demonstrating that steroid therapy for SCR patients can decrease of CAN (7), we did steroid pulse therapy for SCR patients. Need of management in patients diagnosed SCR such as additional anti-rejection treatment or immunosuppression change is still controversial (13) (14) (15) . Rush et al. (11) reported that untreated SCR inflicts permanent tubulointerstitial damage and fibrosis. Nankivell et al. (1) reported that the treatment of SCR patients could reduce clinical acute rejection, one of the causes of CAN. Choi et al. (7) reported clinical significance of SCR in living donor kidney transplantation. They showed the group of patients with SCR in protocol biopsy had lower graft survival rate compared to the group of patients with normal or borderline change in protocol biopsy at 10% after 1∼2 years, 20% after 5∼6 years, 30% after 8∼10 years. This study showed management of SCR can improve short and long-term renal allograft function. Therefore, detection and treatment of SCR is helpful for better renal transplant outcome.
After reports about the significance of treatment of SCR, researches on new method for diagnosis of SCR of renal allograft are continuing. Mao et al. (16) reported new non-invasive method, urine fingerprint analysis, but result of large-scale study will be needed for becoming a widely used test. Until the development of new methods to replace protocol biopsy, diagnosis and treatment of SCR through routine protocol biopsy must be considered to prevent CAN.
This study has several limitations. The most important limitation is that the two groups divided according to protocol biopsy were not identical. Because this study was retrospective analysis, two groups could not be assigned at random. As shown in Table 1 , numbers of HLA mismatches of two groups known as a risk factor of SCR already were significantly different, and this factor could have been affected to the incidence of SCR in two groups. In order to compare renal function improvement of two groups, the adjustment of factors that may affect the incidence of SCR will be needed. Relatively small number of patients included in long term result analysis compared to number of patients included in short term result analysis also can be an another limitation.
Conclusion
In conclusion, protocol biopsy early after renal transplantation is safe enough to perform routinely. Due to the incidence of SCR is quite high, protocol biopsy should be considered more commonly in patients with risk factors of SCR such as high number of HLA mismatches, 'not to use Simulect ® '. Treatment of SCR detected by protocol biopsy will help to make long-term renal function better.
